Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).

Nicolaus Kröger,Katja Sockel,Christine Wolschke,Wolfgang Bethge,Richard F. Schlenk,Dominik Wolf,Michael Stadler,Guido Kobbe,Gerald Wulf,Gesine Bug,Kerstin Schäfer-Eckart,Christof Scheid,Florian Nolte,Jan Krönke,Matthias Stelljes,Dietrich W. Beelen,Marion Heinzelmann,Detlef Haase,Hannes Buchner,Gabriele Bleckert,Aristoteles Giagounidis,Uwe Platzbecker

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).

2021

PURPOSEIn contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-rela...

Keywords:

Oncology
curative treatment
Medicine
Stem cell
MEDLINE
Internal medicine
Myelodysplastic syndromes
Transplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations